ASP Isotopes Inc. (NASDAQ:ASPI) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its stake in ASP Isotopes Inc. (NASDAQ:ASPI - Free Report) by 854.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 211,893 shares of the company's stock after acquiring an additional 189,697 shares during the period. JPMorgan Chase & Co. owned approximately 0.30% of ASP Isotopes worth $960,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. State Street Corp boosted its stake in ASP Isotopes by 12.8% during the third quarter. State Street Corp now owns 853,695 shares of the company's stock valued at $2,373,000 after buying an additional 96,604 shares during the last quarter. Jane Street Group LLC boosted its position in shares of ASP Isotopes by 31.7% during the 3rd quarter. Jane Street Group LLC now owns 145,969 shares of the company's stock valued at $406,000 after acquiring an additional 35,166 shares during the last quarter. Barclays PLC grew its holdings in shares of ASP Isotopes by 438.5% in the third quarter. Barclays PLC now owns 72,330 shares of the company's stock valued at $201,000 after purchasing an additional 58,897 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of ASP Isotopes by 42.7% in the third quarter. Geode Capital Management LLC now owns 1,118,423 shares of the company's stock valued at $3,110,000 after purchasing an additional 334,836 shares in the last quarter. Finally, Sanctuary Advisors LLC bought a new stake in ASP Isotopes in the third quarter worth $66,000. Institutional investors own 16.80% of the company's stock.

ASP Isotopes Trading Up 9.2 %

Shares of NASDAQ:ASPI traded up $0.50 during trading on Friday, hitting $5.90. The company had a trading volume of 616,975 shares, compared to its average volume of 2,352,615. The stock has a market cap of $424.84 million, a price-to-earnings ratio of -9.55 and a beta of 3.44. The company has a debt-to-equity ratio of 0.80, a current ratio of 7.55 and a quick ratio of 7.54. The company has a fifty day simple moving average of $4.80 and a two-hundred day simple moving average of $5.33. ASP Isotopes Inc. has a one year low of $1.86 and a one year high of $9.33.

Insider Transactions at ASP Isotopes

In related news, COO Robert Ainscow sold 66,666 shares of the company's stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $5.75, for a total transaction of $383,329.50. Following the completion of the sale, the chief operating officer now directly owns 1,553,326 shares in the company, valued at $8,931,624.50. This represents a 4.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Paul Elliot Mann sold 316,666 shares of the firm's stock in a transaction dated Thursday, April 17th. The stock was sold at an average price of $5.62, for a total value of $1,779,662.92. Following the completion of the sale, the chief executive officer now directly owns 7,315,454 shares of the company's stock, valued at approximately $41,112,851.48. This represents a 4.15 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 766,667 shares of company stock worth $4,358,502. 21.40% of the stock is currently owned by insiders.

ASP Isotopes Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.